The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguchi said.

AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from ... Revolution Medicines, Quanta Therapeutics, and Roche/Chugai. Mirati’s MRTX1133 is in phase ...

Amgen reported yesterday that full-year 2023 sales of Lumakras were $280 million, a dip on the prior year, while Mirati ... KRAS category comes shortly after AstraZeneca licensed a KRAS G12D ...

On Tuesday, Silexion Therapeutics Corp. (NASDAQ ... SIL-204 inhibits key oncogenic KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D. Intratumoral administration of SIL-204 microparticles ...

oral G12D-preferring multi-KRAS progressing; data readout anticipated in 2025 – RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately ...

Silexion Therapeutics Corp. SLXN revealed new preclinical ... when tested in human pancreatic tumor cell lines harboring KRAS G12D mutations, the most common mutation in pancreatic cancer.

Shares of Silexion Therapeutics surged after the company ... when tested in human pancreatic tumor cell lines harboring KRAS G12D mutations, which is the most common mutation in pancreatic cancer ...

Silexion Therapeutics Corp. announced promising preclinical ... of cancer cell growth in pancreatic tumor cell lines with KRAS G12D mutations. Following previous successes with its first ...

The company is exploring how this promising data can inform an expanded next-generation treatment strategy for KRAS-driven cancers. It expects to announce details of its expanded development plan ...